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Abstract
Background: Herpes simplex virus type 2 (HSV-2) is the most frequent cause of genital ulcer disease worldwide
and has been associated with increased risk for HIV-1 acquisition and transmission. We conducted a cross-sectional
analysis of risk factors for HSV-2 infection among HIV-1 uninfected partners, whose partners were co-infected with
HIV-1 and HSV-2.
Methods: Between November 2004 and April 2007, 3408 HIV-discordant couples, in which the HIV-1 infected
partners were HSV-2 seropositive with CD4 250 cells/mm
3 or greater, were enrolled in an HSV-2 suppression trial to
prevent HIV-1 transmission at 14 sites in 7 African countries. Clinical & behavioral data, HSV-2 and HIV-1 testing
were conducted at enrolment. Univariate and multivariate Poisson regression analyses were performed separately,
by gender of the HIV-1 infected partner.
Results: Among 3354 HIV-1 uninfected participants, 32% were female and overall 71% were HSV-2 seropositive.
Among couples with female HIV-1 infected partners, HIV-1 plasma RNA [aPR 1.03; 95% CI: 0.99 to 1.06; p = 0.11]
and CD4 count [aPR 1.00; 95% CI: 0.98 to 1.01; p = 0.48] in the HSV-2/HIV-1 dually infected female and circumcision
in the HIV-1 uninfected male partner [aPR 0.94; 95% CI: 0.88 to 1.00; p = 0.06] were not associated with reduced
risk of HSV-2 seropositivity, after adjusting for other factors.
Conclusions: In this cross-sectional analysis of African HIV-1 serodiscordant heterosexual couples with prevalent
HSV-2 infection in the HIV-1 infected partner, HIV-1 plasma RNA and CD4 count in the dually-infected partner and
male circumcision in the HIV-1 uninfected partner were not associated with HSV-2 concordance.
Trial Registration: ClinicalTrials.gov NCT00194519
Background
Herpes simplex virus type 2 (HSV-2) is the most com-
mon cause of genital ulcer disease (GUD) worldwide.
HSV-2 prevalence in sub-Saharan Africa ranges from
27-57% in men to 30-74% in women [1,2] and is higher
in HIV-1 infected persons [3]. Epidemiologic studies
suggest synergy between HIV-1 and HSV-2 that facili-
tates the spread of both viruses, with HSV-2 increasing
HIV-1 susceptibility and infectiousness [4] and HIV-1
infection increasing HSV-2 reactivation frequency [5].
The increased risk of HIV-1 transmission and acquisi-
tion due to HSV-2 infection in the context of an overall
high risk of HIV-1 transmission among stable, hetero-
sexual HIV-1 serodiscordant couples (one partner HIV-
1 infected and the other HIV-1 uninfected) [6], which
are highly prevalent in Africa [7], make evaluation of
risk factors for HSV-2 within HIV-1 serodiscordant cou-
ples from diverse parts of Africa of interest.
We conducted a cross-sectional analysis of risk factors
for HSV-2 seropositivity in >3300 HIV-1 uninfected
members of African HIV-1 serodiscordant couples in
which the HIV-1 infected partner was dually-infected
with HSV-2. In particular, we sought to assess whether
HIV-1 plasma RNA level or CD4 count in the HIV-1
infected partner, as indicators of higher HIV-1 infec-
tiousness and more advanced immunosuppression,
modifies HSV-2 infectiousness, and if male circumcision
in the HIV-uninfected partners of women with HSV-2/
HIV-1 dual infection protected them from HSV-2
acquisition.
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Study Population
From November 2004 to April 2007, 3408 heterosexual
HIV-1 discordant couples from 14 sites in Botswana,
Kenya, Rwanda, South Africa, Tanzania, Uganda and
Zambia were enrolled into the Partners in Prevention
HSV/HIV Transmission Study, a randomized clinical trial
of suppressive acyclovir therapy to reduce sexual HIV-1
transmission from HSV-2/HIV-1 dually-infected women
and men to their HIV-1 uninfected partners [7]. HIV-1
discordant couples were eligible for enrolment into the
trial if they were sexually active and planning to remain
partnered for at least 24 months and if the HIV-1-
infected participant was HSV-2 infected, had a CD4
count 250 cells/mm
3 or greater, was not on antiretroviral
therapy, and was not pregnant. HIV-1 uninfected mem-
bers of the discordant couples could be either HSV-2 ser-
opositive or seronegative. Clinical and behavioral data
collected at study enrolment were used for this analysis.
Laboratory Methods
HIV-1 testing was done using 2 rapid assays in parallel,
most commonly Determine HIV-1/2 (Abbott Diagnos-
tics), Uni-Gold HIV-1 (Trinity Biotech), or Capillus
HIV-1/HIV-2 (Trinity Biotech) and paired positive rapid
assay results were confirmed by HIV-1 EIA [7]. At all
study sites, HSV-2 serostatus was determined using Her-
peSelect HSV-2 gG2-based EIA (Focus Technologies).
Given the results of previous studies using this assay in
African cohorts, a cut-off value of ≥3.5 was chosen to
define seropositivity, in order to improve test specificity
[8-10]. CD4 quantification was performed for HIV-1
infected participants at 6-month intervals using standard
flow cytometry. Plasma HIV-1 RNA was quantified
using the COBAS Ampliprep/COBAS TaqMan real-time
HIV-1 RNA assay, version 1.0 (Roche Diagnostics, India-
napolis, IN). All HIV-1 and HSV-2 serologic results
were confirmed by Western blot, performed at the Uni-
versity of Washington [11].
Statistical Analysis
Data were entered onto standard case report forms and
faxed to a central database at the University of Washing-
ton. Analysis was done using SAS version 9.1 (SAS Insti-
tute, Cary, NC). Univariate and multivariate analyses were
performed using Poisson regression with HSV-2 status of
the partner participant as the outcome variable. In order
to examine male circumcision and to allow for other pos-
sible gender differences in transmission risk, separate ana-
lyses were performed for male and female HIV-1 infected
participants. Backward elimination, starting with all vari-
ables significant at p < 0.1 in univariate regression, was
performed to select a final multivariate model.
Ethical Approval
Institutional review boards at the University of
Washington and at all collaborating site organizations
approved study procedures. All participants provided
written informed consent. The trial was registered
through ClinicalTrials.gov (NCT00194519).
Results
Characteristics of study population
Of 3408 enrolled HIV-1-uninfected participants, 3354
were eligible for this analysis (54 were excluded because
either they or their partner were ineligible for the study,
based on confirmatory HIV-1 or HSV-2 testing). HIV-1
seronegative partners had a median age of 35 years and
1084 (32%) were female. Couples reported a median of
4 sex acts in the month prior to enrollment (IQR 2-8).
T h es e r o p r e v a l e n c eo fH S V -2 among HIV-1 seronega-
tive partners was 71% overall; 63% in men versus 89% in
women (p < 0.001). By study design, all HIV-1 infected
partners were co-infected with HSV-2. Median CD4
count among HIV-1 infected partners was 462 cells/
mm
3 (IQR 347-631) and median plasma HIV-1 RNA
was 4.1 log10 copies/mL (IQR 3.3-4.7).
Risk factors for HSV-2 infection among HIV-1 uninfected
partners
Among male HIV-1 uninfected partners of HIV-1/HSV-
2 dually infected females, older age (adjusted prevalence
ratio [aPR] 1.11, p < 0.001), a greater number of chil-
dren (aPR 1.02 per 1 child increase, p < 0.001) and
greater number of years living together (aPR 1.07, per 1
year increase, p = 0.009) were significantly associated
with HSV-2 infection (Table 1). Characteristics of the
female HIV-1 infected partner associated with HSV-2
infection in their male HIV-1 uninfected partners
included having herpetic lesions observed on genital
exam at enrollment (aPR 0.92, p = 0.04), other sexual
partners (aPR 1.28, p = 0.05), and using vaginal drying
agents (aPR 1.08, p = 0.05). Circumcised HIV-1 unin-
fected men were at slightly decreased risk for HSV-2
(aPR 0.94, p = 0.06), although this did not achieve statis-
tical significance.
Among female HIV-1 uninfected partners of HIV-1/
HSV-2 dually-infected males, only older age (aPR 1.08,
p < 0.0001) and greater number of years of education
(aPR 0.90, p = 0.001) of the HIV-1 infected partner
were associated with HSV-2 seropositivity.
Notably, neither HIV-1 plasma RNA level [aPR 1.03;
95% CI: 0.99 to 1.06; p = 0.11] nor CD4 count [aPR
1.00; 95% CI: 0.98 to 1.01; p = 0.48], factors that might
indicate increased HSV-2 infectiousness [12], were asso-
ciated with increased risk of HSV-2 infection in HIV-1
uninfected partners.
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Page 2 of 6Table 1 Population characteristics and risk factors for HSV-2 seropositivity among HIV-1 uninfected members of African HIV-1 serodiscordant partnerships
HIV-1 uninfected female partners of males dually-infected with HSV-2
and HIV-1 (N = 1084)
HIV-1 uninfected male partners of females dually-infected with HSV-
2 and HIV-1 (N = 2270)
HSV-2
negative
(n = 123)
# (%) or
median (IQR)
HSV-2
positive
(n = 961)
# (%) or
median (IQR)
Prevalence
ratio
(95% CI)
p-
value
Adjusted
Prevalence
Ratio
#
(95% CI)
p-
value
HSV-2
negative
(n = 841)
#( % )o r
median (IQR)
HSV-2
positive
(n = 1429)
# (%) or
median (IQR)
Prevalence
ratio
(95% CI)
p-
value
Adjusted
Prevalence
ratio
#
(95% CI)
p-
value
Characteristics of HIV-1/HSV-2
dually-infected partner
Genital lesions at enrollment 27 (22%) 233 (24.2%) 1.01
(0.97, 1.07)
0.6 202 (24%) 287 (20.1%) 0.92
(0.85, 0.99)
0.028 0.92
(0.85, 0.99)
0.04
CD4 count 424 (335-566) 424
(333-571)
1.00
(0.99, 1.01)*
0.66 484
(358-669)
482
(354-659)
1.00
(0.98, 1.01)*
0.48
Plasma HIV-1 RNA 4.35
(3.71-4.95)
4.32
(3.67-4.87)
0.99
(0.97, 1.02)
0.64 3.92
(3.13-4.50)
3.96
(3.25-4.55)
1.03
(0.99, 1.06)
0.11
Has any other sexual partners 9 (7.3%) 78 (8.1%) 1.01
(0.94, 1.09)
0.76 7 (0.8%) 26 (1.8%) 1.26
(0.99, 1.59)
0.058 1.28
(1.00, 1.63)
0.047
Characteristics of HIV-1 uninfected
partner
Age 26 (22-30) 31 (26-39) 1.09
(1.06, 1.12)
†
<.001 1.08
(1.06, 1.11)
†
<.001 32 (28-39) 37 (31-44) 1.17
(1.14, 1.21)
†
<.001 1.11
(1.06, 1.15)
<.001
Years of education 8 (7-12) 8 (6-10) 0.88
(0.83, 0.93)
†
<.0001 0.90
(0.85, 0.96)
†
0.0011 9 (7-12) 9 (7-12) 0.89
(0.82, 0.97)
†
0.01 !
Has any other sexual partners 1 (1.5%) 4 (0.8%) 0.91
(0.65, 1.28)
0.59 31 (7.9%) 67 (10.0%) 1.09
(0.94, 1.27)
0.27
Gender-specific characteristics
Male partner is circumcised (physical exam) 37 (30.1%) 329 (34.3%) 1.02
(0.98, 1.07)
0.36 483 (57.4%) 760 (53.2%) 0.94
(0.88, 1.00)
0.049 0.94
(0.88, 1.00)
0.0614
Female partner uses hormonal
contraceptives
18 (14.6%) 157 (16.3%) 1.01
(0.96, 1.07)
0.63 160 (19.0%) 279 (19.5%) 1.01
(0.93, 1.10)
0.77
Female uses vaginal drying 24 (19.5%) 196 (20.4%) 1.01
(0.95, 1.06)
0.82 156 (18.5%) 322 (22.5%) 1.09
(1.01, 1.18)
0.025 1.08
(1.00, 1.17)
0.051
Couple characteristics
‡
Couple is married 94 (76.4%) 776 (80.7%) 1.03
(0.98, 1.09)
0.26 589 (70.0%) 1078 (75.4%) 1.11
(1.03, 1.20)
0.005
Duration of sexual relationship 4 (2-8) 7 (3-15) 1.06
(1.04, 1.09)
†
<.001 4 (2-7) 6 (3-10) 1.18
(1.13, 1.24)†
<.001
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6Table 1 Population characteristics and risk factors for HSV-2 seropositivity among HIV-1 uninfected members of African HIV-1 serodiscordant partnerships
(Continued)
Years living together 3 (1-6) 6 (3-13) 1.06
(1.03, 1.09)
†
<.001 3 (1-6) 5 (2-10) 1.20
(1.15, 1.26)†
<.001 1.07
(1.02, 1.13)
0.009
Number of children 1 (1-3) 3 (1-4) 1.03
(1.02, 1.04)
<.001 2 (1-3) 2 (1-4) 1.05
(1.04, 1.07)
<.001 1.02
(1.01, 1.04)
0.001
Informal housing 50 (41.3%) 348 (37.5%) 0.98
(0.94, 1.03)
0.41 346 (42.5%) 540 (38.9%) 0.95
(0.89, 1.01)
0.099
Number of sex acts with study part-ner in
previous month (median, IQR)
3 (2-7) 4 (2-8) 1.02
(0.99, 1.05)†
0.26 4 (2-8) 4 (2-8) 0.96
(0.92, 1.01)
†
0.13
Any sex acts with partner in previous
month
114 (92.7%) 885 (92.1%) 0.99
(0.92, 1.07)
0.82 796 (94.6%) 1342 (93.9%) 0.95
(0.83, 1.09)
0.47
Any unprotected sex with study partner in
previous month
32 (26.0%) 259 (27.0%) 1.01
(0.96, 1.05)
0.83 245 (29.1%) 451 (31.6%) 1.04
(0.97, 1.12)
0.23
Enrollment site in Eastern (vs. southern)
Africa
78 (63.4%) 593 (61.7%) 0.99
(0.95, 1.04)
0.71 509 (60.5%) 874 (61.2%) 1.01
(0.95, 1.08)
0.76
# Multivariate risk ratios, adjusted for other factors in the model as shown.
* Risk ratio of HSV2 positivity for every 100 ct increase in CD4.
† Risk ratio of HSV2 positivity for every increase of 10.
‡ As reported by HIV-1 uninfected participant.
(Note: Length of sexual relationship strongly associated with age of partner, rho = 0.66, p < .0001.)
! Years of education was not a significant risk factor for HSV-2 seropositivity in male HIV-1 uninfected partners
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6Discussion
In this multi-national study of 3354 African HIV-1 sero-
discordant couples in which one partner was dually-
infected with HIV-1 and HSV-2, HIV-1 plasma RNA
and CD4 count of the HIV-1 infected partner were not
significantly associated with HSV-2 infection concor-
dance in the HIV-1 uninfected partner. Furthermore,
despite a recent prospective clinical trial reporting asso-
ciation of male circumcision with reduced HSV-2 acqui-
sition [13], male circumcision in male HIV-1 uninfected
partner was only marginally protective against HSV-2
infection in our cross-sectional multivariate analysis.
Prevalence of HSV-2 in the HIV-1 uninfected partner
was high in our study (63% in men and 89% in women)
compared to other African cohorts [14,15], possibly due
to the high rate of HSV-2 transmission reported in
stable, long-term partnerships [16,17]. Also consistent
with other studies [18-20], HSV-2 infection at enroll-
ment in the HIV-1 uninfected partner was significantly
associated with older age and was higher among women
compared to men. The former may indicate that age is
a surrogate for duration of sexual exposure in these cou-
ples [21].
A limitation of this cross-sectional study was the
inability to determine temporal relationships of HIV-1
and HSV-2 infection in the dually-infected partner or
recency of HSV-2 infection in the HIV-uninfected part-
ners, thus limiting our analysis of behavioral correlates
with HSV-2 infection. HSV-2 concordance may reflect
HSV-2 transmission within the couple or acquisition
outside the partnership. Our study eligibility criteria
included that couples be sexually active and intend to
remain together; as such we may have selected for older,
more stable couples.
Conclusions
In summary, among African HIV-1 serodiscordant cou-
ples in which all the HIV-infected partners were dually
infected with HSV-2, 71% of their HIV-1 uninfected
partners had HSV-2 infection, and HSV-2 infection in
the HIV-uninfected partner was not associated with
HIV-1 plasma RNA and CD4 count in the HIV-infected
partner, or male circumcision in the HIV-1 uninfected
partner. Given the need to identify interventions to
reduce HSV-2 transmission, future research should
focus on prospective analysis of risk factors for HSV-2
transmission, which will be conducted in this cohort.
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